Dr. Bang-Ping Jiann: PDE5 inhibitors in erectile dysfunction
نویسنده
چکیده
tau.amegroups.com © Translational Andrology and Urology. All rights reserved. The 2016 Huaxia Medical Forum—Genitourinary Tumor & The 2016 Greatwall International Translational Andrology and Urology Forum (GUT-HMF 2016 & GITAU 2016) was held at the Tianjin Convention Center in Tianjin, China from April 15–17, 2016. We are honored to invite Dr. Bang-Ping Jiann for an interview after his speech on “Penile rehabilitation with PDE5 inhibitors in men after nerve-sparing radical prostatectomy”. Dr. Bang-Ping Jiann (Figure 1) is Professor of National Yang-Ming University, Taipei, Taiwan and Director of Division of Basic Medical Research, Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Dr. Jiann is Vice-President and Deputy Director of the committee on male sexual dysfunction, Asian Association of Andrology. He is associate editor for the Sexual Medicine since 2012 and editorial member for the World Journal of Men’s Health since 2014. Dr. Jiann has also published over 100 original researches and invited review articles in peer-reviewed international medical journals and 10 book chapters.
منابع مشابه
AB020. Penile rehabilitation with PDE5 inhibitors in men following radical prostatectomy
Post-radical prostatectomy (RP) erectile dysfunction (ED) remains a challenge for the urologist. Despite the improvements in surgical technique, ED occurs between 20% and 90% in patients treated with bilateral nerve-sparing RP. Patient factors, cancer selection, type of surgery, surgical techniques, and surgeon factors represent the key significant contributors to erectile function recovery. Th...
متن کاملPhosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
Prostate cancer (PCa) is the most common solid neoplasm diagnosed in developed countries. Nerve-sparing radical prostatectomy (NS-RP) has been widely accepted as the best choice treatment for localised PCa. However, erectile dysfunction (ED) and urinary incontinence are commonly observed after NS-RP. Using meta-analysis, we examined if phosphodiesterase type 5 inhibitors (PDE5-Is) could improve...
متن کاملPhosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
INTRODUCTION Over the past 15 years, the discovery and development of oral medications that selectively inhibit the enzyme phosphodiesterase type 5 (PDE5) have revolutionised the treatment of erectile dysfunction (ED). Currently, three PDE5 inhibitors are widely available clinically, i.e., sildenafil, vardenafil and tadalafil. New PDE5 inhibitors, including avanafil and udenafil, are now in cli...
متن کاملComparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer
Phosphodiesterase type-5 inhibitors (PDE5-Is) have been recommended as first line therapy for erectile dysfunction for patients received nerve-sparing radical prostatectomy for prostate cancer. We examed the efficiency of PDE5-Is and considered the optimal application. Systematic search of PubMed, Embase and the Cochrane Library was performed to identify all the studies. We identified 103 studi...
متن کاملRecent insights into androgen action on the anatomical and physiological substrate of penile erection.
Erectile response is centrally and peripherally regulated by androgens. The original insights into the mechanisms of action of androgens were that androgens particularly exert effects on libido and that erections in response to erotic stimuli were relatively androgen-independent. It was shown that sexual functions in men required androgen levels at the low end of reference values of testosteron...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2016